Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LRAT | O95237 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AMY2A | P04746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26170073 | 1.00 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL26736014 | 0.93 | AMY2A (0.51) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14600975 | 0.91 | MEN1 (0.41) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL17879097 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL17480019 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL23640180 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL26471008 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL19074567 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL12454820 | 0.90 | HSD17B10 (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14639596 | 0.90 | MEN1 (0.49) | MEN1LRATTRPV1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285577-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | THE UNIVERSITY OF TOKYO (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230277721-A1 | TOPICAL HEMOSTATIC POWDER COMPOSITION AND PREPARATION METHOD THEREFOR | THERACION BIOMEDICAL CO., LTD. (KR) | 2023-09-07 | — | — | US | disclosed |
| US-20180105620-A1 | HYDROPHILIC COPOLYMER WITH PENDANT THIOL GROUPS | ALCON INC. (CH) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285577-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | DDOST, ALG1, STT3B | MEN1 1036/4885LRAT 1161/4885TRPV1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.